The AO trauma CPP bone infection registry: Epidemiology and outcomes of Staphylococcus aureus bone infection

Abstract

Bone infection represents a serious complication of orthopedic surgery and Staphylococcus aureus is the most common pathogen. To improve the understanding of host-pathogen interaction, we developed a biospecimen registry (AO Trauma CPP Bone Infection Registry) to collect clinical data, bacterial isolates, and serum from patients with S. aureus bone infection. A prospective multinational registry with a

Single‐stage revision of MRSA orthopedic device‐related infection in sheep with an antibiotic‐loaded hydrogel

“…Despite surgical debridement and appropriate local and systemic antimicrobial therapy, failure rates for ODRI remain up to 30%, with methicillin‐resistant Staphylococcus aureus (MRSA) often identified as a risk factor for treatment failure 8‐11 . A major limitation of this treatment protocol is the PMMA itself.…”

Distinct expression trend of signature antigens of Staphylococcus aureus osteomyelitis correlated with clinical outcomes

“…Before 2011, comprehensive healthcare insurance had not yet been fully implemented in China, and some patients had not received proper medical care due to economic reasons, which played a decisive role in the prolongation of the bone infection 17 . On the basis of data collected in our studies, the bone infections caused by S. aureus have obvious regional characteristics 13,14 . Most of these patients had lived in mountainous, far from the cities and had not been exposed to hospital‐derived S. aureus .…”

“…This study was the second phase of the 2012 AOCPP Bone Infection in China, 13 and was approved by the Ethics Committees of the First Affiliated Hospital of ZMU and the Southwest Hospital of Chongqing (SHC) From January 2014 to December 2017, we enrolled 55 patients with S. aureus long bone infection (monomicrobial or polymicrobial) confirmed by clinical culture of the specimen that was collected from during surgical irrigation and debridement at the ZMU and SHC. The inclusion criteria are (1) patients aged 18 years or older; (2) confirmed oxacillin‐/methicillin‐sensitive Staphylococcus aureus (OSSA/MSSA) or methicillin‐resistant Staphylococcus aureus (MRSA) infection involving a long bone (femur, tibia, fibula, humerus, radius, ulna, and clavicle) with one (or a combination) of the osteomyelitis, fracture fixation hardware/prosthetic joint infection, infection around an arthroplasty; (3) be able to understand the content of the informed consent form (ICF) and able to participate in the clinical investigation; (4) signed written ICF.…”

“…All infection pathogenic bacteria were determined by clinical laboratory examinations at the administration hospital and confirmed again by the Joint Orthopaedic Research Center of ZMU and the University of Rochester Medical Center (URMC) at ZMU (Tables 1, 2 and Figure 1). 12–14 …”

“…Meanwhile, due to the Chinese government's regulations prohibiting the export of human materials from China, a central laboratory was established to manage and analyze Chinese specimens at Zunyi Medical University (ZMU) in China 12 . On the basis of patients recruited for AO Clinical Priority Program (AOCPP) Bone Infection in China, 12,13 this study aims to study seven antigens (IsdA, IsdB, and IsdH, Amd, Gmd, CHIPS, and SCIN) associated with S. aureus bone infections, and provide an understanding of the clinical significance of serum antibody levels during the course of bone infection.…”